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2
N,N’-CoCl2](OTf)·0.25H2O. 
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Romerosa*b  
 
Synthesis, characterization and the antiproliferative activity of the 
new bimetallic complex [RuCp(PPh3)2-µ-dmoPTA-1кP:2k
2
N,N’-
CoCl2]OTf·0.25H2O are described. The stability of the complex was 
studied under air and N2 in CDCl3, DMSO, water and the cell 
culture medium, at room temperature and 40 °C. The complex 
showed an enhanced antiproliferative activity (up to six-fold) 
when compared with its parent complex 
[RuCp(PPh3)2(HdmoPTA)]
2+
 against human lung, cervix, breast, and 
colon solid tumor cell lines. 
The biological activity of a metal complex depends on its 
components, metal and ligands, but also on its behaviour in a 
cellular medium, as showed by the intense research targeted 
since 1965 to understand how the first found antiproliferative 
active complex, cisplatin,1 acts. Despite of the long time 
passed, this complex continues to be in medical use although it 
produces adverse effects on patients and its activity remains 
unknown.2 Replacing platinum is mandatory to obtain less 
toxic and cheaper metal complexes but active against cancers.3 
Organometallic complexes have shown interesting 
antiproliferative activity.4 In particular, {Ru-η6-arene}-
complexes incorporating aqua-soluble phosphines have  
attracted considerable interest due to their hydrophilic 
phosphane coligands and the possibility of the inclusion of 
labile groups prone to be substituted.5 The study of the 
mechanism of action of these complexes is nowadays in 
progress as it has been proved that proceeds through a 
different path than that known for platinum complexes.1-6 
Recently, we observed that the ruthenium complex 
[RuClCp(PPh3)(HdmoPTA)]
+, containing the ligand HdmoPTA+ 
(HdmoPTA = 3,7-H-3,7-dimethyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane),7 (the so-called 1st generation, 
Fig. 1) showed one of the strongest ability to inhibit in vitro the 
proliferation of human cancer cell lines.8 Notably, this complex 
exhibits an excellent antiproliferative profile against the colon 
cancer cell line WiDr (GI50 = 1.7 µM), which is known to exhibit 
a large resistance to cisplatin exposure. Our early results have 
demonstrated that the ligand (HdmoPTA)+ is able to 
coordinate by both P and NCH3 atoms,
7
 giving rise to bis-
heterometallic complexes with differentiate antiproliferative 
activity. They showed GI50 values in the range 0.8–6.5 μM, 
which are comparable to those obtained for the standard 
anticancer drug cisplatin.8,9 A step ahead in the synthesis of 
more active antiproliferative complexes was obtained by 
exchanging the Cl by a PPh3 in [RuClCp(PPh3)(HdmoPTA)]
+, 
leading to the new complex [RuCp(PPh3)2(HdmoPTA)]
2+ (1) (the 
so-called 2
nd 
generation, Fig. 1). The antiproliferative activity of 
1·2OTf against human lung, cervix, breast, and colon solid 
tumor cell lines (GI50 = 0.17−0.29 μM, Table 1) was much 
higher than that observed for [RuClCp(PPh3)(HdmoPTA)]
+ but 
also for the known platinum drugs and the ruthenium 
complexes described until now.1 
Altogether, the obtained results suggested that our next step 
should be targeted to the synthesis of bis-heterometallic-complexes 
by coordination of a metal unit to dmoPTA-NCH3 atoms of 1, 
expecting that the resulting bis-metallic complex displays an 
enlarged activity than starting complex and previous complexes 
[RuClCp(PPh3)(HdmoPTA)]
+ and [RuClCp(PPh3)-µ-dmoPTA-
1κP:2κ2N,N’-MQ] (M = Co, Ni, Zn; Q = acac, Cl2).
8,9 Herein we report 
the synthesis, spectroscopic characterization and X-ray crystal 
structure of the Ru-Co complex [RuCp(PPh3)2-µ-dmoPTA-
1κP:2κ2N,N’-CoCl2](OTf)·0.25H2O (2·OTf·0.25H2O), and its 
antiproliferative activity against a panel of human cell lines.  
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The synthesis of 2·OTf·0.25H2O (Scheme 1) was achieved by 
deprotonation of [RuCp(PPh3)2(HdmoPTA)](OTf)2 (1·2OTf) with 
potassium tert-butoxyde and further reaction with CoCl2·6H2O. 
 
 
 
 
 
 
 
 
 
 
Single crystals good enough for their analysis by single crystal X-
ray diffraction were obtained by evaporating at room temperature 
under nitrogen from a EtOH solution of 2 (ESI). Complex 
2·OTf·0.25H2O was found to be sparingly soluble in water (S25ºC,H2O 
< 0.5 mg/mL) but soluble in a range of organic solvents such as 
chloroform (S25ºC,CHCl3 > 97.3 mg/mL). Its 
31P{1H} NMR (CDCl3) shows 
a multiplet at 211.35 ppm and a doublet at 40.77 ppm, far away 
from the chemical shift observed in 1·2OTf (∆δ (2dmoPTA – 1HdmoPTA) = 
172.75 ppm; ∆δ (2PPh3 – 1PPh3) = 54.86 ppm), as a consequence of 
the paramagnetism of the Co(II) coordinate to the dmoPTA-NCH3. A 
similar behavior was observed for parent bimetallic complexes 
[RuClCp(PPh3)-µ-dmoPTA-1κP:2κ
2
N,N’-CoIIQ] (Q = acac, Cl2).
9,10 The 
1H NMR signals were not possible to be undoubtedly assign but 
13C{H} NMR signals for aromatics (141.32-127.71 ppm) and Cp 
(91.03 ppm, which is shifted 5.54 ppm to that found in 1). 
The determination of the crystal structure (see ESI for the data) of 
this complex provided the final support to its Ru-Co bimetallic 
character. The crystal structure is shown in Fig. 2, selected 
crystallographic parameters, bonds and angles are respectively 
display in Table S1, S2 and S3. The asymmetric unit of 
2·OTf·0.25H2O is constituted by two bi-metallic cationic complex 
[RuCp(PPh3)2-µ-dmoPTA-1кP:2k
2N,N’-CoCl2]
+, two OTf anion and 
two disordered 0.25 water molecules. The distribution of ligands 
around rutheniums (Fig. 2a) in both complex molecules are basically 
the same to those found for previous structures containing 
HdmoPTA-Ru.1,7 The coordination PdmoPTA-Ru distance is found to be 
2.370(9) Å, which is slightly shorter than in 1 (2.3208(1) Å)1 but 
greater than that found for [RuClCp(PPh3)HdmoPTA] (2.2767(3) Å).
7 
The PPPh3-Ru distances are similar in one of the molecule (2.378(4) 
Å, 2.370(9) Å), which are similar to those in 1 (average value: 2.3777 
Å), but significantly different in the other one (2.2911(9) Å, 
2.3438(8) Å). Interestingly, the P1-Ru1-P3 angle in 2 is shorter to 
that in 1 (92.77(3)o versus 96.58(4)°) but 2 displays the largest angle 
(P2-Ru1-P3 = 99.73(3)°). This angle is also larger than those in bis-
metallic complexes [RuClCp(PPh3)dmoPTA-MCl2] (M = Ni, Zn) (av. 
96.8°)9 and {[RuClCp(PPh3)dmoPTA-M(acac-к
2
O,O´)2] (M = Co, Ni, 
Zn) (av. 99.0°).10 Additionally, the angle Cl3-Co1-Cl2 in 2 is found to 
be 126.7(10)°, which is in the range of those found in complexes 
[RuClCp(PPh3)dmoPTA-MCl2] [M = Ni (129.4(3)°), Zn (121.8(6)°)], 
unfortunately the respective complex with M= Co(II) was not 
structurally characterized yet.9 No significant differences were 
found in the rest of the bond distances and angles with respect to 
parent dmoPTA-cyclopentadienyl Ru(II) complexes. The crystal 
packing diagram (Fig. 2b) shows weak intermolecular interactions 
among the molecules (C18A-H18A···F3 = 3.458(4), C23A-H23A···F2 = 
3.259(4) Å) and C-H/π interactions between the aromatic centroid 
and the adjacent phenyl-C-H groups (centroid-to-C-H distances from 
3.311(3) Å to 3.463(4) Å), which probably provide an additional 
stabilization of the structure of the complex.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The antiproliferative activity tests of 2·OTf·0.25H2O using the 
standard protocol (see ESI) on six humans solid tumour cells lines 
together with those for 1·2OTf and cisplatin, which were also tested 
at the same time for the sake of comparison, are shown in Table 1.  
 
 
 
 
Cell line (origin) 
 A549 
(lung) 
HBL-100 
(breast) 
HeLa 
(cervix) 
SW1573 
(lung) 
T-47D 
(breast) 
WiDr 
(colon) 
1
 0.29 
(0.09) 
0.21 
(0.04) 
0.17 
(0.04) 
0.20 
(0.02) 
0.25 
(0.04) 
0.20 
(0.03) 
       
2
 0.062 
(0.019) 
0.088 
(0.008) 
0.084 
(0.022) 
0.054 
(0.013) 
0.21 
(0.05) 
0.065 
(0.010) 
       
cisPt 4.9 
(0.2) 
1.9 
(0.2) 
1.8 
(0.5) 
2.7 
(0.4) 
17 
(3.3) 
23 
(4.3) 
 
 
 
 
Complex 2·OTf·0.25H2O showed an enhanced antiproliferative 
activity in five of the six cell lines tested with respect to 1·2OTf and 
much better activity than cisplatin. In addition, the salt CoCl2·6H2O 
was tested, confirming that it is inactive against cell lines checked. 
Next, we studied the effect of complex 2·OTf·0.25H2O on the cell 
cycle of the same panel of tumour cell lines (Fig. S8). Similarly, to 
that observed for complex 1·2OTf,1 the exposure of studied cell 
lines to 2·OTf·0.25H2O produces the accumulation of cells in the G1 
Scheme 1. Synthesis of 2·OTf 0.25H2O 
Fig. 2. A ball and sticks perspective drawing of 2 (a). Dashed lines 
represent the selected intermolecular interactions (b). For the sake of 
clarity most of the hydrogen and the dashed line C23A-H23A···F2 were 
omitted. 
Table 1. GI50 values (µM) of complexes 1·2OTf
a, 2·OTf·0.25H2O
b and cisplatin 
against several human solid tumor cells lines.
 
(a) From ref. 1. (b) Means of at least three experiments. 
Fig. 1. Antiproliferative activity of cisplatin, 1st, 2nd generation HdmoPTA-Ru 
and the complex presented in this work against human solid tumour cell lines 
A549; HBL-100; HeLa; SW1573; T47D and WiDr, indicted as a range. 
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compartment of the cell cycle. From this result we anticipate that 
both complexes display a similar mechanism of action against the 
studied cell lines. 
Complex 2·OTf·0.25H2O in DMSO-d6 at room temperature 
releases in 10 min. the {CoCl2} unit, which is transformed in the 
[Co(DMSO)4Cl2] complex,
11 to provide the neutral deprotonated 
complex [RuCp(PPh3)2(dmoPTA)]
+. In contrast, addition of DMSO 
and quick further addition of water or the cell culture medium 
avoid the fast elimination of the {CoCl2} unit. Therefore, the 
protocol to study the antiproliferative activity of 2·OTf·0.25H2O 
does not produce a fast decomposition of the compound. The 
evolution of a similar solution at room temperature and 40 °C 
showed that the complete release of the {CoCl2} unit was achieved 
after 2 hours. Further an additional reaction was observed: the 
elimination of one PPh3. This reaction is so slow that after 24 h at 
room temperature and 16 h at 40 °C only a 5 % of the phosphine 
was eliminated. When a similar reaction was preformed but 
containing 5 eq. of NaCl one of the PPh3 in 2 was exchanged by Cl
-, 
giving rise to the stoichiometric production of complex 
[RuClCp(PPh3)(HdmoPTA)]
+.7 However, in a lipophilic environment 
the behavior of 2·OTf·0.25H2O was showed to be different. In a 
CDCl3 solution the complex first releases a PPh3 molecule and 
further the {CoCl2} unit, indicating that its stability is quite 
dependent on the environment. 
In summary, the obtained results indicate that the coordination of 
a {CoCl2} unit to 1-HdmoPTA-NCH3 atoms leads to a new bis-metallic 
complex with antiproliferative activity enhanced than starting 
complex 1·2OTf, which was one of the most active anticancer agent 
known until now. The NMR studies targeted to know how stable is 
the complex 2·OTf·0.25H2O in cell culture medium, pointing out 
that the Co-unit is released slowly but at the moment there are no 
evidences to know if this reaction is significantly produced before 2 
goes into the cancer cell. In any case the CoCl2 salt was found 
inactive against the studied cancer cells.12 This result support that 
this salt outside the cell could not be the responsible of the 
enhanced activity of 2·OTf·0.25H2O but inside the cell could be and 
antiproliferative agent and/or synergize the activity of other 
compounds. If this is correct, complex 2·OTf·0.25H2O acts as a 
“Trojan horse” to introduce into the cell the {CoCl2} unit. It is 
important to stress that cobalt is an essential microelement in the 
human body, playing an important physiological role in the 
metabolism of iron, synthesis of hemoglobin, methionine 
metabolism and as a component of Vitamin B12.
13 The exchange of 
one of the PPh3 bonded to the metal by a ligand in the solution was 
also observed, being this reaction slower than the release of {CoCl2} 
unit. It is reasonable to suppose that this reaction should occur into 
the cell. This reaction was observed to be the fastest one when the 
complex was dissolved in a lipophilic solvent as CDCl3. Therefore, 
not only 2·OTf·0.25H2O but also products formed by its 
decomposition could be the real responsible of its so high 
antiproliferative activity. However, it is evident that the 
combination in 2 of the metal units containing Ru and Co leads to a 
significant enhance of the antiproliferative activity of both metal 
units separated. 
More detailed kinetic studies and biological experiments would 
be necessary to establish the exact role of all possible products 
derived from 2·OTf·0.25H2O and to understand how this compound 
displays a so large antiproliferative activity, better than most of the 
known metal complexes.14 Additionally, new bis-metallic Ru-M 
complexes are in synthesis to know if different to Co metals 
produce similar active antiproliferative compounds. Our findings 
open the possibility to develop new organometallic drugs that can 
rely on selecting metals and ligands to modulate the 
pharmacological properties of the final drug. 
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The complex [RuCp(PPh3)2-µ-dmoPTA-1кP:2k
2
N,N’-CoCl2]·OTf·0.25H2O shows an antiproliferative activity 
significantly better (up to 354-fold for WiDr-colon cells) than cisplatin and with enhanced activity up to six-
fold than its starting complex [RuCp(PPh3)2(HdmoPTA)]
2+
. 
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